Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib Maintenance Post-HSCT for IDH1-mutant Myeloid Neoplasms
NCT03564821Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivosidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 28 Days. Started Jan 2019; status: completed.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03564821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564821.